Secukinumab‐induced subacute cutaneous lupus erythematosus

Conforti, Claudio; Retrosi, Chiara; Giuffrida, Roberta; Vezzoni, Roberta; Currado, Damiano; Navarini, Luca; Farinazzo, Eleonora; Dell’Aquila, Carmen; Nan, Katiuscia; Meo, Nicola di; Zalaudek, Iris

doi:10.1111/dth.13417

Cited by 11 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secukinumab was stopped, and topical mometasone furoate cream and prednisolone cream cleared lupus erythematosus after about 8 weeks. Two other similar cases were diagnosed in a 58‐year‐old woman 6 and a 62 year‐old‐man 46 after 1 month of secukinumab treatment for Ps. Unlike classic lupus erythematosus, patients with drug‐induced lupus erythematosus generally recover within weeks (sometimes months) after discontinuation of the putative offending drug, which is the best evidence for this diagnosis 93 .…”

Section: Discussionmentioning

confidence: 89%

“…The onset time of those AESI ranged from 3 days 52 to 96 weeks 60 . A total of 24 AESI was identified (Table 1), including adiposity, 14 alopecia areata, 15 acute autoimmune hemolytic anemia, 16 bullous eruption, 17,18,32 crystalline corneal deposition, 19 drug‐associated vasculitis (including leucocytoclastic vasculitis, IgA vasculitis [henoch‐schönlein purpura], and Behcet's disease), 5,20–24,61 eczematous drug eruption, 11,25–31,62 erectile dysfunction, 35 granuloma annulare, 36–38 hidradenitis suppurativa, 39,40 hypertrichosis, 41 IBD (including Crohn disease [CD], ulcerative colitis [UC], and IBD undefined [IBDU]), 9,12,13 interstitial pneumonia, 42,43 drug‐induced lupus erythematosus, 6,45–47 multiple lentigines, 48 perianal dermatophytosis, 51 pompholyx (dyshidrotic eczema), 33,34 pseudolymphoma, 52 pyoderma gangrenosum, 53,54 raynaud's phenomenon, 55 scleroderma, 57 stomatitis (such as lichenoid mucositis, oral lichen planus, and angular cheilitis), 44,49,50,56 uveitis, 58 and vitiligo 59,60 …”

Section: Resultsmentioning

confidence: 99%

“…The searches generated 1426 potentially articles that matched our predefined search strategy, of which 55 were included in this review (Figure 1): 2 clinical studies, 11,12 2 review, 9,13 50 case reports 5,6,14–61 and 1 case series, 62 published between 2016 and 2021. More than 1077 patients (aged 18–74 years) experienced AESI after secukinumab treatment for Ps, PsA, AS, spondyloarthritis (SpA), and/or palmoplantar psoriasis (PPP).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Review of secukinumab‐induced adverse events of special interest and its potential pathogenesis

Liang

Zhang

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Although secukinumab has demonstrated high efficacy and favorable safety in moderate‐to‐severe psoriasis and psoriatic arthritis, patients developing adverse events of special interest (AESI) were reported increasingly in real‐world practice. A systematic literature search of the PubMed database was conducted to identify clinical studies or case reports on secukinumab‐induced AESI. More than 1077 patients (aged 18–74 years) from 55 studies were reported to have 24 AESI 3 days to 96 weeks after secukinumab treatment. The four most common AESI was inflammatory bowel disease (n > 1000), eczematous drug eruption (n > 30), drug‐associated vasculitis (n = 8), and drug‐induced lupus erythematosus (n = 4). Most of these AESI were only mild to moderately severe and resolved after secukinumab discontinuation without or with symptomatic treatment. Secukinumab has the potential to develop a number of AESI by probably dysregulating the different expression of polar T‐cell axes (Th1, Th2, Th17, Th22, and/or Treg) and driving various cytokines in some patients. Physicians should be aware of these AESI for timely diagnosis and proper treatment.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Review of secukinumab‐induced adverse events of special interest and its potential pathogenesis

Liang

Zhang

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Particularly relevant to the rheumatologist is the potential for biologic therapies including TNF- inhibitors, IL-17 inhibitors, IL-12/23 inhibitors and cytotoxic T-lymphocyte associated protein-4 therapy to induce SCLE. [39][40][41][42] Rowell's syndrome is an entity that can be associated with SLE, DLE, or SCLE, in which patients develop erythema multiforme-like lesions and have a speckled ANA pattern. 25 Sjogren's syndrome is often a concomitant autoimmune disorder found in patients with SCLE and is more commonly associated with SCLE than other CLE subtypes.…”

Section: Subacute Cutaneous Lupus Erythematosusmentioning

confidence: 99%

Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist

2022

View full text Add to dashboard Cite

The majority of patients with systemic lupus erythematosus (SLE) have cutaneous manifestations at some point in their disease. The skin findings in lupus erythematosus are classified as lupus-specific or lupus-nonspecific based on histopathologic findings. Lupus-specific skin diseases include chronic cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and acute cutaneous lupus erythematosus. There are subsets of skin lesions within each group and the likelihood of associated SLE varies amongst them. Lupus nonspecific lesions are more common in patients with SLE and tend to coincide with active systemic disease. Lupus nonspecific lesions may be seen as a feature of another disease process, including other connective tissue diseases. It is important for the rheumatologist to be familiar with the spectrum of cutaneous disease in lupus erythematosus to help prognosticate the likelihood of systemic disease and ensure patients receive timely dermatologic care with the goal of controlling disease activity to prevent damage.

show abstract

“…Brodalumab, ixekizumab and secukinumab target the IL‐17 pathway, with the former targeting directly at the IL‐17A receptor and the latter two inhibiting IL‐17A 1 . There are only three cases of secukinumab‐induced LE reported in the literature 2–4 . To our knowledge, there is no report to date on SCLE associated with brodalumab.…”

Section: Figurementioning

confidence: 99%